Log In
Print
BCIQ
Print
Print this Print this
 

hGH-CTP, Lagova (MOD-4023, PF-06836922)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionLong-acting human growth hormone (hGH) combined with the company's carboxyl terminal peptide (CTP) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationGrowth hormone deficiency
Indication DetailsTreat growth hormone deficiency (GHD)
Regulatory Designation

U.S. - Orphan Drug (Treat growth hormone deficiency (GHD))

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$570.0M

$295.0M

$275.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today